Crossmark

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Crossref DOI link: https://doi.org/10.1038/s41467-022-32591-8

Published Online: 2022-08-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Renouf, Daniel J. https://orcid.org/0000-0002-7597-6089
Loree, Jonathan M. https://orcid.org/0000-0001-8189-2132
Knox, Jennifer J.

Topham, James T.

Kavan, Petr

Jonker, Derek

Welch, Stephen

Couture, Felix

Lemay, Frederic

Tehfe, Mustapha

Harb, Mohammed

Aucoin, Nathalie

Ko, Yoo-Joung

Tang, Patricia A.

Ramjeesingh, Ravi https://orcid.org/0000-0001-5584-3505
Meyers, Brandon M.

Kim, Christina A. https://orcid.org/0000-0003-3847-2583
Du, Pan

Jia, Shidong

Schaeffer, David F.

Gill, Sharlene https://orcid.org/0000-0003-3306-3617
Tu, Dongsheng

O’Callaghan, Chris J
Funding

Funding for this research was provided by:

Terry Fox Research Institute (1078)
License Information

Text and Data Mining valid from 2022-08-26

Version of Record valid from 2022-08-26
More Information

Article History

Received: 5 May 2022

Accepted: 8 August 2022

First Online: 26 August 2022

Competing interests

: P.D. and S.J. are employees of Predicine. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below